Partnering News

---

06/17/2010
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway more

---

05/05/2010
Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization of Vaginorm
Bayer Schering Pharma AG, Germany, announced that it has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics, Inc. for the development and commercialization of Vaginorm, an intra-vaginal application of dehydroepiandrosterone (DHEA). A Phase III clinical program for Vaginorm in the treatment of symptoms of vulvovaginal atrophy and female sexual dysfunction in postmenopausal women has been initiated. more

---

03/17/2010
Bayer Schering Pharma and Prometheus to Apply Novel Diagnostic Platform to Oncology Therapeutic Candidates
Bayer Schering Pharma AG, Germany, has entered a research collaboration and license agreement with Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company. more

---

12/01/2009
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
Bayer Schering Pharma AG, Germany, will develop a new BiTE antibody for the treatment of solid tumors in collaboration with the biopharmaceutical company Micromet, Inc. In January 2009, both companies had entered into an option, license and collaboration agreement. By exercising the option today, Bayer Schering Pharma has triggered a joint collaboration on the development of the BiTE antibody against an undisclosed solid tumor target through the completion of Phase I clinical trials, at which point Bayer will assume full control of the further development and commercialization of the antibody. BiTE antibodies are designed to direct the body's cell-destroying T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. more

---

10/08/2009
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Bayer Schering Pharma AG, Germany, will provide its development candidate florbetaben, a so called PET (positron emission tomography) tracer, to the Swiss-based biopharmaceutical company AC Immune SA, to support a clinical trial in the field of Alzheimer´s disease (AD). This study is conducted to develop a therapy option for the treatment of AD. Bayer´s novel PET tracer florbetaben will be applied for imaging of beta-Amyloid deposition in the brain of patients undergoing the phase I clinical testing of AC Immune´s Alzheimer´s vaccine ACI-24. In this collaboration, florbetaben will be tested for the very first time in the development of a potential therapeutic for Alzheimer’s patients. more

---

09/03/2009
Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients
Bayer Schering Pharma AG, Germany has entered into a global agreement with Algeta ASA, Oslo, Norway for the development and commercialization of Alpharadin™, a novel alpha-emitting radiopharmaceutical, based on radium-223. Alpharadin is currently being evaluated in a global Phase III trial for the treatment of bone metastases in symptomatic hormone-refractory prostate cancer (HRPC) patients. more

---

07/09/2009
Bayer acquires exclusive rights to Bioton’s insulin SciLin
Bayer Schering Pharma AG (BSP), Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton’s Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acquires the exclusive right to market and distribute insulin produced by Bioton under the trade name of SciLin in China. The contract and payment guarantee the exclusive commercial delivery of this recombinant insulin to Bayer in China with a secured supply of the product for the next 15 years. more

---

06/29/2009
Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
License Agreement with Celera Corporation on five cancer target molecules

Bayer Schering Pharma AG, Germany, has entered into an exclusive license agreement with Celera Corporation, California, USA, providing Bayer Schering Pharma with access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. These therapeutic targets were identified by Celera's proteomics discovery platform. more

---

06/02/2009
Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement
Bayer HealthCare and Genzyme Corporation said today that they have received regulatory approvals for the strategic alliance announced on March 31, 2009. With these approvals, the legal closing of the transaction was completed on May 29, 2009. more

---

04/30/2009
Bayer and Regeneron extend development program for VEGF Trap-Eye
Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. today announced that the companies will extend their development program for VEGF Trap-Eye, an investigational new substance for the treatment of certain eye diseases, to include Central Retinal Vein Occlusion (CRVO). The companies plan to initiate a Phase III program evaluating the efficacy and safety of VEGF Trap-Eye in the treatment of this disease in the second half of this year. CRVO is caused by obstruction of the central retinal vein that leads to retinal injury and loss of vision. The retina can also become "ischemic" (starved for oxygen), resulting in the growth of new, inappropriate blood vessels that can cause further vision loss and more serious complications. more

---

04/28/2009
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer
Bayer HealthCare AG, Germany has entered into a global agreement with Ardea Biosciences, Inc., San Diego California, USA (Nasdaq: RDEA) focused on the development of small molecule mitogen-activated ERK kinase (MEK) inhibitors for the treatment of solid tumors. These kinases are believed to play an important role in cancer cell proliferation, apoptosis and metastasis, as well as inflammation. The lead compound in this program, RDEA119, is currently being evaluated in advanced cancer patients of different tumor types as a single agent in a Phase I study as well as in combination with sorafenib (Nexavar®, Bayer HealthCare, Onyx Pharmaceuticals) in a Phase I/II study. more

---

03/31/2009
Bayer HealthCare and Genzyme Corporation Enter New Strategic Agreement
Berlin, Germany and Tarrytown, NY, USA, March 31, 2009 – Bayer HealthCare announced today that it has entered a new strategic agreement with Genzyme Corporation, Cambridge, MA. more

---

03/18/2009
Bayer and Tsinghua University establish joint research center in China
Bayer HealthCare AG, Germany, and Tsinghua University in Beijing, China have signed a comprehensive collaboration agreement to enter into a strategic partnership. The two partners will establish a joint research center at Tsinghua University, the Bayer-Tsinghua (Institute of Biomedicine) Research Center of Innovative Drug Discovery. Professor Yigong Shi, a renowned structural biologist, currently Director of the Department of Biological Sciences and Biotechnology and Vice Dean of the Institute of Biomedicine of Tsinghua University, was appointed Director of this joint Research Center. more

---

01/12/2009
Exclusive licensing option for solid tumor antibody
Bayer Schering Pharma AG, Germany, has acquired an exclusive option for a collaboration and licensing agreement with Micromet, Inc., a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Bayer Schering Pharma will pay Micromet a 4.5 million Euro fee to secure a one-year option on a specific BiTE antibody. more

---

01/08/2009
Bayer Schering Pharma enhances research in cancer imaging Licensing agreement with Hamamatsu Photonics K.K., Japan
Bayer Schering Pharma AG and Hamamatsu Photonics K.K., Japan have signed a licensing agreement for the use of novel substances in the field of molecular imaging for cancer. Within the agreement, Bayer Schering Pharma acquires the worldwide exclusive rights for research, development and commercialization of a group of molecules that specifically bind to malignant tumor cells. In combination with positron emission tomography (PET), these tracers could potentially improve the diagnosis of a variety of cancers. more

---

12/04/2008
Bayer expands men’s healthcare portfolio
Licence agreement for innovative testosterone gel also covers emerging markets

Bayer Schering Pharma will develop and commercialise ProStrakan’s Tostrex® in Canada, Latin America, the Middle East, Africa, Asia and the Pacific region. A respective agreement between Bayer Schering Pharma and ProStrakan Group plc. was signed which grants Bayer exclusive marketing rights in these regions. more

---

09/30/2008
Bayer starts new research cooperation in Asia
Research collaboration with National University of Singapore signed
Overall investment volume of 10 million Euro

Bayer Schering Pharma and the National University of Singapore (NUS) have agreed to cooperate in the field of pre-clinical cancer research. The initial collaboration with the NUS will focus on three joint projects in the field of oncology. more

---

09/16/2008
Bayer HealthCare acquires German DIREVO Biotech AG
Strengthening Bayer HealthCare’s commitment to develop innovative biologicals

Bayer HealthCare AG acquires the German biotech company DIREVO Biotech AG, Cologne. With the acquisition of the biotech company specialized in protein engineering, Bayer strengthens the research competence in biologicals of its pharmaceutical division Bayer Schering Pharma more

---

09/10/2008
Bayer Intensifies Research in Early Diagnosis of Alzheimer’s Disease
Licensing agreement with Nagasaki University signed

Bayer Schering Pharma and the University of Nagasaki (Japan) have signed a licensing agreement on the use of novel substances for molecular imaging. Being used as tracers in Positron Emission Tomography (PET), these compounds could make it possible to allow an early diagnosis of Alzheimer’s disease. more

---

08/08/2008
Bayer Acquires Preclinical Anti-cancer Program from Nycomed
Bayer Schering Pharma AG, Germany, is expanding its oncology pipeline with the acquisition of a preclinical oncology program from Nycomed, a pharmaceutical company headquartered in Switzerland. The agreement comprises two potential drug candidates and an extensive set of back-up compounds targeting a kinase critical for growth and survival of cancer cells. more

---

07/02/2008
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen’s hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in the third quarter of 2008. The total transaction is valued at US-Dollar 90 million upfront with a final, potential milestone payment of US-Dollar 30 million. This agreement includes a license to use Maxygen’s MolecularBreeding™ technology, a novel research platform, for exploiting gene targets. more